BCL2L1 and prostate adenocarcinoma: Our results are in partial agreement with the data reported by Baritaki et al., who demonstrated time-dependent reductions in the levels of other antiapoptotic proteins such as Bcl-XL, survivin, and X-linked inhibitor of apoptosis (XIAP) in MZB-stimulated PC-3 prostatic adenocarcinoma cells [39].